ERYTECH completes enrollment in its Phase III study in Acute Lymphoblastic Leukemia Post author:admERY Post published:September 10, 2013 Post category:Newsroom ERYTECH announces the completion of the enrollment of patients in its pivotal Phase III study in Acute Lymphoblastic Leukemia (ALL). You Might Also Like ERYTECH Provides Business and Financial Update for the First Quarter of 2022 May 12, 2022 ERYTECH to Webcast Presentation at Jefferies 2017 London Healthcare Conference November 14, 2017 ERYTECH appoints Dr. Iman El-Hariry as Chief Medical Officer July 15, 2015